Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Administration of B7-H3 targeted chimeric antigen receptor-T cells induce regression of glioblastoma.

Literature DB >> 33767145

Administration of B7-H3 targeted chimeric antigen receptor-T cells induce regression of glioblastoma.

Xin Tang¹, Yuelong Wang¹, Jianhan Huang¹, Zongliang Zhang², Fujun Liu¹, Jianguo Xu¹, Gang Guo², Wei Wang², Aiping Tong³, Liangxue Zhou⁴.

Abstract

Entities: Chemical

Mesh：

Substances：

Year: 2021 PMID： 33767145 PMCID： PMC7994554 DOI： 10.1038/s41392-021-00505-7

Source DB: PubMed Journal: Signal Transduct Target Ther ISSN： 2059-3635

× No keyword cloud information.

5 in total

1. Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma.

Authors: Christine E Brown; Behnam Badie; Michael E Barish; Lihong Weng; Julie R Ostberg; Wen-Chung Chang; Araceli Naranjo; Renate Starr; Jamie Wagner; Christine Wright; Yubo Zhai; James R Bading; Julie A Ressler; Jana Portnow; Massimo D'Apuzzo; Stephen J Forman; Michael C Jensen
Journal: Clin Cancer Res Date: 2015-06-09 Impact factor: 12.531

2. Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy.

Authors: Christine E Brown; Darya Alizadeh; Renate Starr; Lihong Weng; Jamie R Wagner; Araceli Naranjo; Julie R Ostberg; M Suzette Blanchard; Julie Kilpatrick; Jennifer Simpson; Anita Kurien; Saul J Priceman; Xiuli Wang; Todd L Harshbarger; Massimo D'Apuzzo; Julie A Ressler; Michael C Jensen; Michael E Barish; Mike Chen; Jana Portnow; Stephen J Forman; Behnam Badie
Journal: N Engl J Med Date: 2016-12-29 Impact factor: 91.245

3. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma.

Authors: Donald M O'Rourke; MacLean P Nasrallah; Arati Desai; Jan J Melenhorst; Keith Mansfield; Jennifer J D Morrissette; Maria Martinez-Lage; Steven Brem; Eileen Maloney; Angela Shen; Randi Isaacs; Suyash Mohan; Gabriela Plesa; Simon F Lacey; Jean-Marc Navenot; Zhaohui Zheng; Bruce L Levine; Hideho Okada; Carl H June; Jennifer L Brogdon; Marcela V Maus
Journal: Sci Transl Med Date: 2017-07-19 Impact factor: 17.956

4. Differential expression of 2IgB7-H3 and 4IgB7-H3 in cancer cell lines and glioma tissues.

Authors: Zhenxin Wang; Jianfeng Yang; Yanbo Zhu; Yun Zhu; Bin Zhang; Yinghui Zhou
Journal: Oncol Lett Date: 2015-08-14 Impact factor: 2.967

5. B7-H3 as a Novel CAR-T Therapeutic Target for Glioblastoma.

Authors: Xin Tang; Shasha Zhao; Yang Zhang; Yuelong Wang; Zongliang Zhang; Meijia Yang; Yanyu Zhu; Guanjie Zhang; Gang Guo; Aiping Tong; Liangxue Zhou
Journal: Mol Ther Oncolytics Date: 2019-07-23 Impact factor: 7.200

5 in total

6 in total

1. Genome-scale CRISPR-Cas9 screen reveals novel regulators of B7-H3 in tumor cells.

Authors: Shasha Zhao; Yuelong Wang; Nian Yang; Min Mu; Zhiguo Wu; Hexian Li; Xin Tang; Kunhong Zhong; Zongliang Zhang; Cheng Huang; Ting Cao; Meijun Zheng; Guoqing Wang; Chunlai Nie; Hui Yang; Gang Guo; Liangxue Zhou; Xi Zheng; Aiping Tong
Journal: J Immunother Cancer Date: 2022-06 Impact factor: 12.469

Review 2. Tumor buster - where will the CAR-T cell therapy 'missile' go?

Authors: Chunrun Qu; Hao Zhang; Hui Cao; Lanhua Tang; Haoyang Mo; Fangkun Liu; Liyang Zhang; Zhenjie Yi; Lifu Long; Luzhe Yan; Zeyu Wang; Nan Zhang; Peng Luo; Jian Zhang; Zaoqu Liu; Weijie Ye; Zhixiong Liu; Quan Cheng
Journal: Mol Cancer Date: 2022-10-19 Impact factor: 41.444

Administration of B7-H3 targeted chimeric antigen receptor-T cells induce regression of glioblastoma.

1. Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma.

2. Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy.

3. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma.

4. Differential expression of 2IgB7-H3 and 4IgB7-H3 in cancer cell lines and glioma tissues.

5. B7-H3 as a Novel CAR-T Therapeutic Target for Glioblastoma.

1. Genome-scale CRISPR-Cas9 screen reveals novel regulators of B7-H3 in tumor cells.

Review 2. Tumor buster - where will the CAR-T cell therapy 'missile' go?

Review 3. Emerging Biomarkers for Immunotherapy in Glioblastoma.

Review 4. Immunotherapy of glioblastoma: Recent advances and future prospects.

Review 5. Site-Specific Considerations on Engineered T Cells for Malignant Gliomas.

Review 6. B7-H3/CD276: An Emerging Cancer Immunotherapy.